Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice

J Antimicrob Chemother. 2005 Apr;55(4):587-90. doi: 10.1093/jac/dki024. Epub 2005 Feb 22.

Abstract

Objectives: We investigated the effects of fluconazole and micafungin for the therapy of deep-seated candidiasis in a cyclophosphamide-induced immunosuppressed mouse model.

Methods: We used the experimental model of intraperitoneal fungal abscess caused by Candida albicans, as described previously.

Results and conclusions: Micafungin efficacy was equal to that of fluconazole in one-tenth dosage even in peritonitis. We also assessed the short-term (24 h) and long-term (8 days) therapeutic effects after the end of therapy. Although the therapeutic effect of fluconazole was similar to that of micafungin at 24 h after the end of therapy, the effect of micafungin was superior to that of fluconazole at 8 days after the end of therapy.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antifungal Agents / therapeutic use*
  • Candidiasis / drug therapy*
  • Candidiasis / immunology
  • Cyclophosphamide / pharmacology
  • Dose-Response Relationship, Drug
  • Echinocandins
  • Female
  • Fluconazole / therapeutic use
  • Immunocompromised Host*
  • Immunosuppressive Agents / pharmacology
  • Lipopeptides
  • Lipoproteins / therapeutic use*
  • Micafungin
  • Mice
  • Mice, Inbred ICR
  • Microbial Sensitivity Tests
  • Peptides, Cyclic / therapeutic use*
  • Specific Pathogen-Free Organisms

Substances

  • Antifungal Agents
  • Echinocandins
  • Immunosuppressive Agents
  • Lipopeptides
  • Lipoproteins
  • Peptides, Cyclic
  • Cyclophosphamide
  • Fluconazole
  • Micafungin